XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Revenue $ 6,234 $ 8,119 $ 19,998 $ 18,579
Cost of revenue 4,636 5,699 14,579 13,952
Gross profit 1,598 2,420 5,419 4,627
Operating expenses:        
Research and development 704 518 1,865 1,397
Selling 434 290 1,281 895
General and administrative 1,450 1,490 4,410 3,937
Loss on disposition of Tantaline 162
Impairment charge 111
Total operating expenses 2,588 2,298 7,829 6,229
Operating income (loss) (990) 122 (2,410) (1,602)
Other income (expense):        
Interest income 173 43 400 74
Interest expense (6) (18) (5)
Foreign exchange income (expense) (107) 42 (250)
Other income 70 5 91 11
Total other income (expense), net 237 (59) 515 (170)
Income (loss) before income tax (753) 63 (1,895) (1,772)
Income tax expense 11 1
Net income (loss) $ (753) $ 63 $ (1,906) $ (1,773)
Income (loss) per common share - basic $ (0.11) $ 0.01 $ (0.28) $ (0.26)
Income (loss) per common share - diluted $ (0.11) $ 0.01 $ (0.28) $ (0.26)
Weighted average common shares        
Basic 6,789,487 6,736,764 6,787,415 6,730,263
Diluted 6,789,487 6,740,692 6,787,415 6,730,263